title: Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines.
abstract: OBJECTIVE
  A meeting of a Canadian group with significant experience and knowledge in HIV management, consisting of five physicians, a pharmacist and an AIDS researcher, was convened. Their goal was to develop guidance for Canadian HIV-treating physicians on the appropriate use of raltegravir (MK-0518, Isentress(R), Merck Frosst Canada Inc) in HIV-infected adults.
  
  
  METHODS
  Evidence from the published literature and conference presentations, as well as expert opinions of the group members, was considered and evaluated to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, as well as from five other physicians and scientists across Canada with expertise in HIV treatment and antiretroviral drug resistance, and experience in the use of raltegravir. The final recommendations represent the core group's consensus agreement once all feedback was considered.
  
  
  CONCLUSIONS
  Recommendations were developed to guide physicians in the optimal use of raltegravir. The issues considered included raltegravir's role in overall treatment strategy, efficacy, durability of effect, rate of viral load reduction, resistance, safety/toxicity, pharmacokinetics and drug interactions.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto;
authors.forename: Anita
authors.initials: A
authors.lastname: Rachlis
authors.forename: Jonathan B
authors.initials: JB
authors.lastname: Angel
authors.forename: Marianne
authors.initials: M
authors.lastname: Harris
authors.forename: Stephen D
authors.initials: SD
authors.lastname: Shafran
authors.forename: Rachel
authors.initials: R
authors.lastname: Therrien
authors.forename: Cécile
authors.initials: C
authors.lastname: Tremblay
authors.forename: Mark A
authors.initials: MA
authors.lastname: Wainberg
references.citation: HIV Med. 2008 Oct;9(8):563-608
references.pmid: 18826546
references.citation: JAMA. 2008 Aug 6;300(5):555-70
references.pmid: 18677028
references.citation: J Clin Pharmacol. 2008 Jun;48(6):726-33
references.pmid: 18441333
references.citation: Clin Infect Dis. 2008 Jul 1;47(1):137-40
references.pmid: 18513146
references.citation: N Engl J Med. 2008 Jul 24;359(4):339-54
references.pmid: 18650512
references.citation: Nat Rev Drug Discov. 2005 Mar;4(3):236-48
references.pmid: 15729361
references.citation: Clin Infect Dis. 2008 Jul 15;47(2):266-85
references.pmid: 18549313
references.citation: Antimicrob Agents Chemother. 2008 Dec;52(12):4338-43
references.pmid: 18838589
references.citation: Lancet. 2008 Jul 26;372(9635):293-9
references.pmid: 18657708
references.citation: J Clin Pharmacol. 2008 Feb;48(2):209-14
references.pmid: 18077730
references.citation: Annu Rev Pharmacol Toxicol. 2009;49:377-94
references.pmid: 18928385
references.citation: PLoS Med. 2008 Jul 29;5(7):e164
references.pmid: 18666826
references.citation: Lancet. 2006 Aug 5;368(9534):466-75
references.pmid: 16890833
references.citation: J Antimicrob Chemother. 2009 Apr;63(4):795-804
references.pmid: 19221102
references.citation: N Engl J Med. 2008 Jul 24;359(4):355-65
references.pmid: 18650513
references.citation: Lancet. 2007 Jul 7;370(9581):29-38
references.pmid: 17617270
references.citation: Antimicrob Agents Chemother. 2008 Sep;52(9):3253-8
references.pmid: 18625763
references.citation: AIDS. 2007 Nov 12;21(17):2315-21
references.pmid: 18090280
references.citation: AIDS. 2008 Jul 11;22(11):1382-4
references.pmid: 18580624
references.citation: AIDS. 2008 Oct 18;22(16):2097-106
references.pmid: 18832873
references.citation: J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):509-15
references.pmid: 17133211
references.citation: AIDS. 2008 Feb 19;22(4):547-8
references.pmid: 18301075
references.citation: Science. 2000 Jan 28;287(5453):646-50
references.pmid: 10649997
references.citation: J Infect Dis. 2008 Apr 15;197(8):1133-44
references.pmid: 18476292
references.citation: AIDS. 2008 Jun 19;22(10):1224-6
references.pmid: 18525270
references.citation: J Antimicrob Chemother. 2008 Nov;62(5):914-20
references.pmid: 18718922
references.citation: J Acquir Immune Defic Syndr. 2002 May 1;30(1):105-10
references.pmid: 12048370
references.citation: AIDS Patient Care STDS. 2007 Aug;21(8):533-43
references.pmid: 17711378
references.citation: Expert Opin Investig Drugs. 2008 Jan;17(1):97-103
references.pmid: 18095922
references.citation: HIV Med. 2007 Oct;8(7):427-32
references.pmid: 17760734
references.citation: AIDS. 2008 Sep 12;22(14):1890-2
references.pmid: 18753871
references.citation: Antimicrob Agents Chemother. 2009 Jul;53(7):2752-5
references.pmid: 19398643
references.citation: Ann Pharmacother. 2008 Jul;42(7):1048-59
references.pmid: 18577765
references.citation: Lancet. 2007 Apr 7;369(9568):1169-78
references.pmid: 17416261
references.citation: J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):367-73
references.pmid: 19487951
references.citation: AIDS. 2008 May 31;22(9):1091-2
references.pmid: 18520356
references.citation: Lancet. 2007 Apr 14;369(9569):1261-1269
references.pmid: 17434401
references.citation: J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):125-33
references.pmid: 17721395
references.citation: Expert Rev Anti Infect Ther. 2007 Feb;5(1):67-75
references.pmid: 17266455
references.citation: Drug Metab Dispos. 2004 Nov;32(11):1201-8
references.pmid: 15304429
references.citation: Antimicrob Agents Chemother. 2008 Apr;52(4):1351-8
references.pmid: 18227187
references.citation: Top HIV Med. 2008 Apr-May;16(1):62-8
references.pmid: 18441382
references.citation: Clin Pharmacol Ther. 2008 Feb;83(2):293-9
references.pmid: 17713476
references.citation: Drug Metab Dispos. 2007 Sep;35(9):1657-63
references.pmid: 17591678
references.citation: Antiviral Res. 2008 Nov;80(2):213-22
references.pmid: 18625269
references.citation: AIDS. 2008 Oct 18;22(16):2187-98
references.pmid: 18832882